Compass Pathways said patients in the second of its two pivotal psilocybin trials maintained their treatment response for at least six months, supporting durability ahead of an expected year-end NDA filing. The company framed the data as keeping it on track for regulatory submission. Compass’ pivotal program evaluates psilocybin therapy for treatment-resistant depression, with the newest statement focused on persistence of benefit rather than acute response. For investors and clinicians, durability is a central variable for dosing strategy and comparative positioning against other late-stage depression approaches. The update arrives as Compass continues to translate trial findings into the evidence package it expects to submit to regulators by year-end.